Dr. Alan Low is the Executive Director of Medicines Access Coalition – BC, Primary Care Pharmacist and Pharmacy Lead at BioPro Biologics Pharmacy, a collaborative practice approach, focusing on patient centred care. He is also a Clinical Associate Professor in the Faculty of Pharmaceutical Sciences at UBC and an Instructor and Course Developer with the School of Health Sciences at the Justice Institute of BC (JIBC).

Convinced that pharmacists have much more to offer to the public and the healthcare system, Alan has led the development and implementation of provincial medication management projects in BC and Alberta as well as creating a novel model of community pharmacy practice where interprofessional collaboration is leveraged to improve patient health outcomes.

Within the Faculty of Pharmaceutical Sciences at UBC, Dr. Low is one of the founders of the Faculty based Pharmacists Clinic and helped develop and lead the business case for the Pharmacists Clinic. He is the Course Coordinator for the Pharmacy Practice Management and Leadership Course and Lecturer. In addition, he is also a Board Advisor with the GI Society and sits on the Medical Board of HealthChoicesFirst.com, a patient video education resource. Dr. Low has experience in a wide variety of health and administrative settings including direct patient care in the hospital and clinics, clinical and practice-based research, consultant in healthcare projects and clinical pharmaceutical consulting. He has held positions such as Clinical Pharmacist, Clinical Specialist, Pharmacotherapeutic Specialist within teaching hospitals, as well as Manager of Government Affairs and Medical Affairs, Medical Science Liaison, and Senior Health Sciences Advisor in research-based pharmaceutical companies and was the Chief Operating Officer at Network Healthcare. Alan is a Certified Clinical Densitometrist (CCD), coauthored “The Osteoporosis Book, 4th Edition: Bone Health”, has numerous publications in scientific and health journals, newsletters, and is a founding co-editor of the Pharmacy Management in Canada textbook.

Alan has been an active member and past participant on various committees (with the College of Pharmacists of BC, BC Pharmacy Association, Canadian Pharmacists Association, Canadian Society of Hospital Pharmacists, GI Society, etc). He has interests in the areas of, rheumatology, osteoporosis, gastroenterology, diabetes, and cardiology. Alan enjoys being involved in projects that improve health knowledge translation, healthcare delivery, medical health education and health outcomes research. Alan’s training includes a Bachelor of Science in Pharmacy, a Hospital Pharmacy Residency at St. Paul’s Hospital, and Doctorate of Pharmacy degree at UBC. He is frequently invited to speak at regional, national and international conferences. He strives to develop solutions to close gaps in health care working together with a variety of people.

André Picard is one of Canada’s top health and public policy observers and commentators. He has been a health reporter and columnist for The Globe and Mail, where he has been a staff writer since 1987. He is also the author of six bestselling books.

André is an eight-time nominee for the National Newspaper Awards, Canada’s top journalism prize, and past winner of the prestigious Michener Award for Meritorious Public Service Journalism.

He was named Canada’s first “Public Health Hero” by the Canadian Public Health Association, as a “Champion of Mental Health” by the Canadian Alliance on Mental Illness and Mental Health, and received the Queen Elizabeth II, Diamond Jubilee Medal, for his dedication to improving healthcare.

André is a graduate of the University of Ottawa and Carleton University and has received honorary doctorates from six universities, including UBC and the University of Toronto.

He is a seasoned communicator who employs a conversational style to reach his audience. He enlivens his research and commentary with personal stories to provide context for his audience, including anecdotes from patients and health professionals on the front lines. Fluently bilingual, André will enlighten and pique a sense of curiosity of audience members from all educational backgrounds. Behind the placid exterior lies an inquisitive, perceptive and industrious scribe for whom the work only begins with the official story.

The University of British Columbia recently announced André Picard as one of the Asper Visiting Professors at the School of Journalism, Writing, and Media for the 2020-2021 academic year, winter session.

In 2020, Picard was awarded the The Owen Adams Award of Honour. This award is the highest CMA award available to a non-physician.

Mr. Picard was awarded the 2021 Sandford Fleming Medal for excellence in science communication by the Royal Canadian Institute for Science. Neglected No More was shortlisted for the first Writers’ Trust Balsillie Prize for Public Policy in 2021, and is currently nominated for the 2021 Donner Award, which recognizes the top public policy book written by a Canadian.

Dr. Alan Low is the Executive Director of Medicines Access Coalition – BC, Primary Care Pharmacist and Pharmacy Lead at BioPro Biologics Pharmacy, a collaborative practice approach, focusing on patient centred care. He is also a Clinical Associate Professor in the Faculty of Pharmaceutical Sciences at UBC and an Instructor and Course Developer with the School of Health Sciences at the Justice Institute of BC (JIBC).

Convinced that pharmacists have much more to offer to the public and the healthcare system, Alan has led the development and implementation of provincial medication management projects in BC and Alberta as well as creating a novel model of community pharmacy practice where interprofessional collaboration is leveraged to improve patient health outcomes.

Within the Faculty of Pharmaceutical Sciences at UBC, Dr. Low is one of the founders of the Faculty based Pharmacists Clinic and helped develop and lead the business case for the Pharmacists Clinic. He is the Course Coordinator for the Pharmacy Practice Management and Leadership Course and Lecturer. In addition, he is also a Board Advisor with the GI Society and sits on the Medical Board of HealthChoicesFirst.com, a patient video education resource. Dr. Low has experience in a wide variety of health and administrative settings including direct patient care in the hospital and clinics, clinical and practice-based research, consultant in healthcare projects and clinical pharmaceutical consulting. He has held positions such as Clinical Pharmacist, Clinical Specialist, Pharmacotherapeutic Specialist within teaching hospitals, as well as Manager of Government Affairs and Medical Affairs, Medical Science Liaison, and Senior Health Sciences Advisor in research-based pharmaceutical companies and was the Chief Operating Officer at Network Healthcare. Alan is a Certified Clinical Densitometrist (CCD), coauthored “The Osteoporosis Book, 4th Edition: Bone Health”, has numerous publications in scientific and health journals, newsletters, and is a founding co-editor of the Pharmacy Management in Canada textbook.

Alan has been an active member and past participant on various committees (with the College of Pharmacists of BC, BC Pharmacy Association, Canadian Pharmacists Association, Canadian Society of Hospital Pharmacists, GI Society, etc). He has interests in the areas of, rheumatology, osteoporosis, gastroenterology, diabetes, and cardiology. Alan enjoys being involved in projects that improve health knowledge translation, healthcare delivery, medical health education and health outcomes research. Alan’s training includes a Bachelor of Science in Pharmacy, a Hospital Pharmacy Residency at St. Paul’s Hospital, and Doctorate of Pharmacy degree at UBC. He is frequently invited to speak at regional, national and international conferences. He strives to develop solutions to close gaps in health care working together with a variety of people.

Fred Horne is a Canadian health policy consultant and served as Alberta’s Minister of Health from 2011-2014.

A frequent speaker and panelist on health system issues, he is currently Principal of Horne and Associates, Health Policy Consultants; Senior Advisor to Ottawa-based 3Sixty Public Affairs; and Chair of Mohawk Medbuy Corporation, a national, not-for profit shared services organization.

Horne serves as Adjunct Professor at the University of Alberta’s School of Public Health and volunteers his time to support policy education and patient education and engagement initiatives across the country.

Horne’s career in health policy spans over thirty years. Current areas of focus include value-based health care, seniors care, health system governance and pharmaceutical policy.

Horne also currently serves on the boards of the Canadian Frailty Network (National Centre of Excellence) and Providence Living (BC).

The Digital Cluster is driving the growth and success of Canadian companies by supporting the development of digital solutions to some of industry and society’s biggest challenges. Creating the world’s first federated platform for sharing research data, delivering exceptional wound care through digital imagery and combatting global anti-microbial resistance with data are just of a few of the technologies created through the Cluster’s collaborative innovation model. As CEO, Sue leads the Cluster’s successful development of partnerships with over 1100 organizations across the country, including health authorities, research institutions and post-secondary organizations. The Cluster is accelerating the growth of exceptional organizations and putting Canada on the world stage as a leader in digital health.

Sue also serves on the Boards of TELUS International, CORIX Group of Companies, Own the Podium and Stemcell Technologies. She is past Chair of the Business Council of British Columbia, the Michael Smith Foundation for Health Research and the Greater Vancouver Board of Trade. Sue’s biggest passion is spending time in Canada’s wilderness with her husband, daughters and granddaughters.

Dr. Ian Rongve joined the Ministry of Health in June 2016 as the Assistant Deputy Minister Provincial, Hospital and Laboratory Health Services Division. In May 2020, Ian was appointed Assistant Deputy Minister of the COVID Response and Health Emergency Management Division, ensuring an ongoing, focused response to supporting the health system within the context of COVID-19. In June of 2021, Dr. Rongve was appointed the Assistant Deputy Minister of the Strategy and Innovation Division.

The Strategy and Innovation Division supports British Columbia’s population and patients in accessing new innovations in care, British Columbia’s health services and health infrastructure in developing and scaling novel and sustainable models of delivery and will drive large scale innovation tackling the systems most significant challenges.

Prior to joining the Ministry of Health, Dr. Rongve was the Assistant Deputy Minister, Knowledge Management and Accountability, at the Ministry of Education. From March 2012 to November 2013, he was the Assistant Deputy Minister, Sector Strategy and Quality Assurance Division, at the Ministry of Advanced Education.

Dr. Rongve holds a Ph.D. in economics. He spent eight years as an Assistant Professor at the University of Regina, before moving back to British Columbia and joining the public service. He has worked in senior roles in the Ministries of Finance, Health, Advanced Education and Education.

Kim Wieringa has led the Health Information Systems Division as an Assistant Deputy Minister and Chief Information Officer for Alberta Health for the last 6 years. This is Kim’s second term in Health having previously spent 9 years in two other divisions. Kim has also held positions in 2 other ministries, and in the municipal and banking environments.

As an executive leader overseeing a diverse portfolio, Kim’s strengths include leading teams though change, policy and program design, strategy development, garnering information technology, project management, and complex stakeholder relations.

As a strategist, Ms. Dhaliwal is focused on bringing the transformational power of data and technology to bear against complex problems in healthcare. Harjeet spent 20 years with the UK National Health Service, most recently as Deputy Director of Data Services at NHS England. Here she led on building a national data repository, broadly used by the NHS and government to look at Covid trends to monitor the spread of the virus and implement measures to ensure services and support is available to patients.

Harjeet has been involved with the NHS at a local, regional and national level focused on data, informatics and business intelligence to support better decisions and improve patient outcomes. Away from work, Harjeet has two sons and enjoys spending time with family and friends.

Dr. Indra Joshi has a unique portfolio of experience spanning data/AI strategy and implementation, digital health, health equity and global advisory – whilst remaining true to her professional training as an emergency medic. She is currently working across the global health and research portfolio of Palantir Technologies to enable better use of data to impact health and care.

Dr. Joshi created the NHS AI Lab which led to the development and deployment of over 80 AI technologies into UK health and care, whilst determining the right ethical guidance and regulations to protect patients. She is a Founding Member and Clinical Director of One HealthTech – a volunteer network which exists to drive better equality, diversity, inclusion, and accessibility in health innovation.

Dr. Joshi is a former member of the World Health Organization Digital Health Technical Advisory – supporting digital health programs and policy, artificial intelligence, ethics, and governance in the healthcare ecosystem with a focus on digital health. Most importantly, Indra is a mum to two wonderful little munchkins.

Mary has over 20 years of executive experience in the British Columbia health system including her service as the President and CEO of Vancouver Coastal Health (VCH) from 2014-2020 and prior executive positions of Chief Operating Officer and Vice-President Facilities, Real Estate and Process Improvement.

Throughout her career, Mary’s passion has been to transform the public system to ensure sustainability in the face of growing demand and constrained resources. As CEO of VCH, she encouraged a focus on innovation and discoveries to improve patient health, transform health systems, and directly impact health and economic outcomes. Her longstanding interest in virtual care enabled health providers to continue delivering care to patients and clients across VCH from the early days of the COVID-19 pandemic.

In 2019, Glassdoor, one of the world’s largest employee recruitment sites named Mary as one of Canada’s Top 25 CEOs based on employee reviews. She was named as one of Canada’s Most Powerful Women in 2014 and 2015. Over the past year, Mary led the innovation and research agenda at the B.C. Ministry of Health as the Senior Executive in Residence and the lead for the Partnerships and Innovation Division.

Mary is a graduate of the Harvard Business School’s Master’s of Business Administration program and holds a Bachelor’s and Master’s degree in Industrial Engineering from West Virginia University.

Dr. Matthew Chow is the Chief Mental Health Officer at TELUS Health, a global-leading total health and wellbeing provider – encompassing physical, mental and financial health.

Dr. Chow’s previous experience includes:
1. President of Doctors of British Columbia (2020-21) leading 14,000 physicians through the challenges of the COVID-19 pandemic and a year of historic climate-related disasters
2. Member of the Medical Services Commission, British Columbia’s public health insurance board responsible for over $3 billion in annual public healthcare spending
3. Co-chair of the Specialist Services Committee to improve medical, surgical, diagnostic, and mental health services across British Columbia in partnership with government and physicians
4. Founding medical director of e-Mental Health Services and Strategy at British Columbia Children’s Hospital

Dr. Chow’s personal mission is to enable people to make their highest and best possible contribution to their communities. This aligns with TELUS Health’s focus on total wellbeing: physical, mental, and financial. Dr. Chow and his colleagues weave together ‘high touch’ and ‘high tech’—a global team of compassionate human beings empowered by digital technologies— to create remarkable wellbeing experiences for people worldwide.

Lisa has more than 25 years of experience in academic and healthcare leadership, including more than a decade with the Fraser Health Authority in various clinical director roles. She joined BCIT in 2015 as Associate Dean, Laboratory and Allied Health, and became Dean, School of Health Sciences in 2018. She is responsible for the strategic leadership, and overall operational leadership of the School of Health Sciences that includes Laboratory Sciences and Allied Health, Nursing, Diagnostics, and Medical Imaging, and Specialty Nursing programs. As well, she is providing the overall leadership for the school in the development of the new Health Sciences Centre. In addition to being part of BCIT Leadership Team, a major part of her responsibilities is working with external partners and industry to support the overall economic growth in the province.

Lisa holds an MBA (Executive) from SFU, a Bachelor of Home Economics (Dietetics and Nutrition) from UBC, and a Certificate in Health Care Management from BCIT. Known as a strategic, collaborative, and visionary leader, Lisa is passionate and experienced in leading transformational change. Accomplished in engaging diverse internal and external stakeholders to achieve common goals, Lisa has a strong track record of creating high-performing teams and building trusting relationships.

Dr. Celia Richardson is an experienced leadership, change enablement and learning consultant with over 20 years of experience helping organizations embrace their talent and steer teams through transformational change. ​

Dr. Richardson has extensive global experience in change adoption, learning, leadership and talent development and has lived and worked in Asia, France, the UK and Canada.

She joined Accenture in 2021 as a member of its Talent and Organization/Human Potential practice, previously holding roles at consulting for the NHS in the UK, CIBC and Deloitte.

A professionally trained Coach and Change Management Specialist, Dr. Richardson holds a Doctorate in Education from the University of Toronto and is also a facilitator at the University’s Centre for Continuing and Professional Learning.

Christine Sorensen (she/her) is a registered nurse with a clinical background in Public Health and Communicable Disease management. From 2017-2021, Christine was the President of the BC Nurses’ Union representing 48,0000 nurses and allied health members from across BC. Currently, Christine is enrolled at the University of BC where she is completing a Masters’ in Health Leadership in Policy. In addition, she teaches Canadian Health Policy to prelicensure nursing students. Christine is Metis, the mother of two young men and an avid traveller.

Dr. Martin Dawes is a world expert in primary care who combines research and clinical practice with over 30 years of experience. Following the completion of his PhD, he helped develop a Masters program in Evidence Based Health Care. He has directed the UK Centre for Evidence-Based Medicine in Oxford and was the head of family practice at McGill University and the University of British Columbia. He is the co-founder and scientific director  of GenXys, a medication decision support software company.

I graduated with a Doctor of Pharmacy in 2015 from University of Toronto. I am currently working as a clinical pharmacist and leading the pharmacogenomics implementation team at Specialty Rx Pharmacy.

My area of focus has been in Rheumatology and Hepatology in the past 4 years. I discovered my passion for personalized pharmacy care, specifically pharmacogenomics at UofT during my undergrad, which I had carried through to Pharmacy school. Presently my goal and interest lie in trying to create an optimal infrastructure for pharmacogenomics in an outpatient clinical settings for both patients and providers.

Dr. Ruslan Dorfman is a molecular geneticist with experience in pharmacogenetics, genetics of chronic pain and rare diseases. Dr. Dorfman is a co-founder and Chief Science Officer at GeneYouIn Inc. GeneYouIn provides pharmacogenetics-based medication services to national insurance and disability providers. Dr. Dorfman is co-authored over thirty-six peer-reviewed publications on the genetics of Cystic Fibrosis, disease-modifying genes, pain genetics and pharmacogenetic strategy. For his work, Dr. Dorfman was awarded numerous prestigious scholarships, including the Florence and Theodore Baumritter Ph.D. Scholarship, the CIHR postdoctoral award, and the “Science to Business” CIHR scholarship. Dr. Dorfman is an Adjunct Professor at the Department of Anesthesia at McMaster University.

Dr. Catrina Loucks is an Assistant Professor in the Department of Pediatrics and the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia. Additionally, she is an Investigator at the BC Children’s Hospital Research Institute. She has experience uncovering genetic causes for rare disorders from her MSc work at the University of Calgary, under the supervision of Drs. Micheil Innes and Jillian Parboosingh. She then sought to explore functional impacts of uncovered genetic mutations by pursuing a PhD under the supervision of Dr. Michel Leroux at Simon Fraser University, using the simple roundworm, C. elegans, as a model. As a postdoctoral fellow at the University of British Columbia, Catrina worked with Dr. Bruce Carleton and the Canadian Pharmacogenomics Network for Drug Safety to understand how genetic variation contributes to variable responses to medication. Currently, she is working to improve pain management in women and children by identifying genetic factors that can help predict an individual’s need for, and subsequent response to, specific analgesics. Additionally, she is working to translate genetic discoveries into improvements in clinical care. Together, her work will allow for more individualized risk-benefit decisions for pain management in women and children, while also contributing to the discovery of novel components of pain response pathways that could pave the way for improved pain management strategies with increased safety and effectiveness.

Dr. Faisal M. Khan is an Associate Professor at the University of Calgary. In his clinical role, Dr. Khan works as Director of Hematology Translational Lab at the University of Calgary; as an Associate Clinical Director of Histocompatibility and Immunogenetic Lab (HIL), and as Scientific Lead of Molecular Pathology Program in Alberta Precision Labs.

Dr. Khan obtained his Ph.D. in Human Molecular Genetics in India in 2006. He completed his postdoctoral training and clinical fellowship at the University of Calgary. Dr. Khan is a certified Diplomat of the American Board of Histocompatibility and Immunogenetics (ABHI).

Dr. Khan has more than 21 years of experience in Transplant Immunology, Cancer Genomics, and Histocompatibility and Immunogenetics. Based on his research, Dr. Khan has published over 100 research articles in scientific journals like Science, Blood, Transplantation, and Blood Advances. His research has been recognized by several awards including the American Society of Hematology (ASH) Achievement Awards in 2013, 2015, and 2018; and the American Society for Histocompatibility and Immunogenetics (ASHI) Scholar/Most Clinically Relevant Study awards in 2014, 2019, and 2022.

Dr. Khan has led the development, validation, and implementation of several advanced clinical molecular diagnostic tests including next-generation sequencing-based comprehensive genomic profiling for myeloid malignancies (2017) and solid tumors (2019); Serum-based cytokine profiling, and (3) post-bone-marrow transplantation engraftment monitoring testing. Dr. Khan is co-founder and CEO of OncoHelix Inc. an organization that specializes in providing esoteric cancer genomic and immunology testing.

Dr. Helia Mohammadi is the Chief Data Scientist and Healthcare Industry Lead for Microsoft Canada. She is a thought leader in the healthcare and research industry. With over a decade of experience in research and applied AI, her work has leveraged and extended Machine Learning and Cloud solutions to deeply influence key domains including medical image processing, genomics research, and precision medicine.

As the National AI Ambassador for the Microsoft Canada AI Country plan, Helia has been pivotal in spearheading Canadian Healthcare digital transformation and AI adoption strategy. She has received numerous distinguishing awards and recognitions, including the “Top 30 Influential Women Advancing AI in Canada”.

She strives to empower the healthcare and research community to positively affect quality of life for patients and medical professionals.

Ali Mussavi is the Executive Director for Data Architecture and Governance at Provincial Health Services Authority, where he has worked since 2006. He is a senior technology leader with demonstrated, in-depth knowledge of the British Columbia and Canadian healthcare systems with over 16 years of experience in leadership roles within data analytics including strategy formulation, solution definition, practice building and delivery.

Ali has a track record of leading cross-functional teams of data engineers, architects, and data scientists that have successfully delivered complex programs of work with limited resources and funding. By formulating an analytics vision, implementing best practices, and designing robust solutions he has successfully enabled teams that are sustainable, scalable and promote improvement and growth.

Ali is currently a Ph.D. Candidate of Health Information Science at University of Victoria. He has completed his Master of Health Administration from the University of British Columbia and holds a Medical Doctorate (MD) degree from Iran. He has authored scientific articles focusing on data linkage, data warehousing, and clinical decision support. Combining his medical and health informatics domain knowledge as well as his extensive technology skills in all areas of health analytics, Ali is leading and scaling-up high calibre teams that ultimately could help improve and positively impact patient care and health services in BC.

Dr. Kendall Ho’s academic and research interests fall into the domain of technology-enabled knowledge translation (TEKT) – the use of information technologies to accelerate the incorporation of the latest health evidence into routine practice. Specific directions within TEKT include telehealth, information and communication technologies (ICT) and patient safety, ICT and public engagement, and evidence-based policy translation in eHealth.

Susan Anderson is an accomplished e-Health strategist with 30 years’ experience in healthcare and informatics in Canada. Susan is currently CIO for the Nunavut Ministry of Health, building the new Health Information Unit within the Department. In assuming this role, requirement was to move to Nunavut and become familiar with the culture, values and priorities of Inuit. Susan is an enthusiastic volunteer, including her current role as a Director for CHIMA’s national Board and as the chair of CHIMA’s governance committee. Susan holds a Director role the Toronto Classical Guitar Society’s Board. Susan recently retired from position of senior health consultant for TECHNATION Health Canadian vendor association.

David Helliwell is a software entrepreneur who has spent much of his career building mission-driven companies in the healthcare and cleantech industries. Prior to co-founding Thrive Health in 2017, David co-founded Pulse Energy in 2006, which evolved into the world’s leading energy intelligence software company at the time of its sale in 2014. Thrive Health’s
mission is to make healthcare work better for everyone with innovative patient engagement & clinical decision support tools. Thrive Health is based in Vancouver and has helped over 10 million Canadians through their healthcare journeys.

David is a mentor and angel investor with international healthtech start-ups through the Creative Destruction Lab and has served two terms on the advisory board for the National Research Council’s Industrial Research Assistance Program (IRAP).

Matthew Lehner is co-founder and CTO of OneFeather. His professional life is devoted to empowering Indigenous people to access the rights and entitlements they are afforded through the technology OneFeather produces. He has been working at the intersection of people and technology for over 20 years and brings deep experience designing, building, and bringing user-focused, technology-based solutions to market. ​

​Over the past 7 years, he has worked in leadership roles where he’s facilitated high-growth companies, implemented processes to ensure organizational alignment and operational efficiency, and managed over $5M in acquisitions. ​​

In his current role at OneFeather, Matthew balances the gritty, do-it-all mentality needed from the founding team with the strategic execution you’d expect from an executive with experience in high growth organizations.

Drew McArthur retired from TELUS in 2007 as Vice President Corporate Affairs and Chief Compliance Officer. As Chief Compliance Officer, Drew was responsible for legal and regulatory compliance for all of TELUS’ operations, reporting to the Audit Committee of the Board of Directors. The responsibilities of this role included ensuring TELUS had the appropriate controls, policies and measurements in place to be compliant with many areas of law and regulation. Drew played a key role in the privacy community in Canada as a founding member of the Council of Canadian Chief Privacy Officers and a member of the advisory board of the International Association of Privacy Professionals (IAPP). From June 2016 to April 2018, Drew was the Acting Information and Privacy Commissioner for BC, and is now consulting in the area of privacy. He can be contacted at drew.mcarthur@telus.net.

An innovator in the technology and security industry, Jaime Chanagá serves as Field Chief Information Security Officer (CISO) at Fortinet for Latin America and the Caribbean. He is passionate about helping private, public, and social sector organizations to address their most critical security challenges ensuring their business success. In this role, he serves as an expert, speaker, and cybersecurity advisor for organizations in the region.

Jaime brings a strong track record as a trusted advisor for cybersecurity strategies to customers in Latin America and the Caribbean, coupled with deep experience in international markets, establishing global strategic partnerships and leading digital transformation programs.

Chanagá is an expert information security professional with an exceptional +20-year career track record in information security, technology, privacy, audit, IT architecture, regulatory compliance, and IT governance. Throughout his career, he has been privileged to serve and advise some of the world’s most admired organizations in the United States, Canada, Europe, and Latin America.

His writing includes collaboration as a co-author of the book Corporate Security in the Information Age (Aspatore). Jaime is also member of InfraGard, a partnership between the FBI and the private sector. InfraGard includes businesses, academic institutions, state and local law enforcement agencies, and other participants dedicated to sharing information and intelligence to prevent hostile acts against the United States.

Chanagá is a Certified Information Systems Security Professional (CISSP). He is also a graduate of the U.S. Federal Bureau of Investigation’s (FBI) Citizens Academy, is a Fusion Liaison Officer for the US Department of Homeland Security (DHS) North Texas Fusion Center (NTFC) and is a member of the United States Secret Service (USSS) Cyber Fraud Task Force (CFTF). Jaime speaks fluent Spanish, Portuguese, and English.

With 20 years experience at Alberta Health and 25 years experience in the health sector, Quinn currently is the Executive Director of Information Management at Alberta Health. His areas responsibilities include stewardship of the Alberta Health Information Act, privacy and security, and eHealth strategy and governance. During the pandemic, Quinn was involved in a number of pandemic related IT initiatives such as ABTraceTogether, the Alberta Covid Records QR code, and the Alberta Vaccine Booking System. Quinn has a BSc. Computing Science and a Master of Public Health both from the University of Alberta.

Pamela Snively joined TELUS as Chief Data and Trust Officer in October, 2015. She leads the team responsible for data and privacy governance at TELUS. Pamela also serves TELUS’ commitment to integrity through her leadership of a variety of initiatives, including the Anti-bribery & Corruption and Competition Law programs.

Prior to joining TELUS, Pamela managed the consulting arm of Osler’s privacy and data management practices, AccessPrivacy by Osler. As a lawyer and consultant, she provided a broad range of privacy, risk-management and compliance advice in the private, public and health sectors. She assisted organizations in implementing enterprise risk-management programs; advising on privacy and outsourcing governance and accountability programs; designing and implementing records-management programs; drafting policies, procedures and training materials; managing data breaches and other regulatory investigations; and conducting privacy impact or risk assessments.

Pamela formerly held Chief Privacy and Risk Officer roles in large business process outsourcing companies in Canada.

Mr. Shahbazi has 25+ years of experience as a technology focused leader and operator. He is the Founder, Chairman and CEO of WELL Health Technologies Corp. (TSX:WELL).

WELL is a provider of digital health solutions to doctors and care providers in both the US and Canada. It is also the largest owner & operator of outpatient medical clinics in Canada. The Company currently owns and operates 83 healthcare facilities, and its comprehensive practitioner enablement platform is used by more than 21,000 physicians in Canada alone to power their healthcare practices. WELL is driven by more than 2700 employees and healthcare providers who engage in greater than 4M patient interactions annually.
Hamed also founded TIO Networks (TSXV:TNC) a multi-channel payment solution provider specializing in last minute bill payment and other financial services. TIO was acquired by PayPal (Nasdaq: PYPL) for CAD$304 million in 2017.

Hamed has extensive strategic Mergers, Acquisitions and Divestitures experience as an operator and board member having completed more than 50 successful transactions.

He is a passionate advocate of impact entrepreneurship where new companies aim to do well by doing good. Founders of these types of businesses he describes as “Impactreneurs”. Hamed regularly mentors founders and entrepreneurs of early stage companies and also supports many of them with early stage investments via Impactreneur Capital Corp.

Mr. Shahbazi has been recognized with a. number of awards including but not limited to Business in Vancouver’s CEO of the Year, (2017), Ernst & Young’s Entrepreneur of the Year (2017 and 2022), and Cantech Letter’s TSX Venture Tech “Exec of the Year” (2014 thru 2016). TIO was also awarded with the TSX’s Venture Tech “Stock of the Year” (2014 and 2015).

Adam Crown joined Okta after spending 7+ years in the Healthcare IT industry. During his tenure, he supported health system clients integrating CIAM Identity Providers into patient portals as they expanded their digital front door strategy. He also supported the rollout of the SMART on FHIR API globally. Today, Adam helps support Okta’s Healthcare strategy.

Joel joined Okta with 20+ years of identity experience, working in various customer-facing roles at Microsoft Canada. During his tenure, Joel supported provincial health systems, financial institutions, aerospace companies, and federal departments in Ottawa. Joel holds Microsoft certifications in multiple cloud and on-prem technologies. Today, he specializes in workforce identity at Okta.

Rich leads Accenture’s Global Health Practice, responsible for a network of strategy, consulting, technology, operations and interactive services. For Accenture Health, Rich is responsible for strategic direction, ecosystem relationships, thought leadership, investments and business expansion. Rich is a recognized industry expert with substantial experience helping clients deliver significant cost improvements, improve productivity, and adapt to new industry requirements. He oversees a team of over 20,000 professionals that operate at the intersection of business and technology by combining real-world experience, business and clinical insights, and innovative technologies to drive better health and economic outcomes. Rich has published numerous papers and as a recognized industry spokesperson, he is often quoted on healthcare issues in various media publications including The Wall Street Journal, Forbes and the New York Times. He is responsible for Accenture’s thought leadership that addresses timely topics and challenges facing the health industry.

Dr. Alan Low is the Executive Director of Medicines Access Coalition – BC, Primary Care Pharmacist and Pharmacy Lead at BioPro Biologics Pharmacy, a collaborative practice approach, focusing on patient centred care. He is also a Clinical Associate Professor in the Faculty of Pharmaceutical Sciences at UBC and an Instructor and Course Developer with the School of Health Sciences at the Justice Institute of BC (JIBC).

Convinced that pharmacists have much more to offer to the public and the healthcare system, Alan has led the development and implementation of provincial medication management projects in BC and Alberta as well as creating a novel model of community pharmacy practice where interprofessional collaboration is leveraged to improve patient health outcomes.

Within the Faculty of Pharmaceutical Sciences at UBC, Dr. Low is one of the founders of the Faculty based Pharmacists Clinic and helped develop and lead the business case for the Pharmacists Clinic. He is the Course Coordinator for the Pharmacy Practice Management and Leadership Course and Lecturer. In addition, he is also a Board Advisor with the GI Society and sits on the Medical Board of HealthChoicesFirst.com, a patient video education resource. Dr. Low has experience in a wide variety of health and administrative settings including direct patient care in the hospital and clinics, clinical and practice-based research, consultant in healthcare projects and clinical pharmaceutical consulting. He has held positions such as Clinical Pharmacist, Clinical Specialist, Pharmacotherapeutic Specialist within teaching hospitals, as well as Manager of Government Affairs and Medical Affairs, Medical Science Liaison, and Senior Health Sciences Advisor in research-based pharmaceutical companies and was the Chief Operating Officer at Network Healthcare. Alan is a Certified Clinical Densitometrist (CCD), coauthored “The Osteoporosis Book, 4th Edition: Bone Health”, has numerous publications in scientific and health journals, newsletters, and is a founding co-editor of the Pharmacy Management in Canada textbook.

Alan has been an active member and past participant on various committees (with the College of Pharmacists of BC, BC Pharmacy Association, Canadian Pharmacists Association, Canadian Society of Hospital Pharmacists, GI Society, etc). He has interests in the areas of, rheumatology, osteoporosis, gastroenterology, diabetes, and cardiology. Alan enjoys being involved in projects that improve health knowledge translation, healthcare delivery, medical health education and health outcomes research. Alan’s training includes a Bachelor of Science in Pharmacy, a Hospital Pharmacy Residency at St. Paul’s Hospital, and Doctorate of Pharmacy degree at UBC. He is frequently invited to speak at regional, national and international conferences. He strives to develop solutions to close gaps in health care working together with a variety of people.

Dr. Alan Low is the Executive Director of Medicines Access Coalition – BC, Primary Care Pharmacist and Pharmacy Lead at BioPro Biologics Pharmacy, a collaborative practice approach, focusing on patient centred care. He is also a Clinical Associate Professor in the Faculty of Pharmaceutical Sciences at UBC and an Instructor and Course Developer with the School of Health Sciences at the Justice Institute of BC (JIBC).

Convinced that pharmacists have much more to offer to the public and the healthcare system, Alan has led the development and implementation of provincial medication management projects in BC and Alberta as well as creating a novel model of community pharmacy practice where interprofessional collaboration is leveraged to improve patient health outcomes.

Within the Faculty of Pharmaceutical Sciences at UBC, Dr. Low is one of the founders of the Faculty based Pharmacists Clinic and helped develop and lead the business case for the Pharmacists Clinic. He is the Course Coordinator for the Pharmacy Practice Management and Leadership Course and Lecturer. In addition, he is also a Board Advisor with the GI Society and sits on the Medical Board of HealthChoicesFirst.com, a patient video education resource. Dr. Low has experience in a wide variety of health and administrative settings including direct patient care in the hospital and clinics, clinical and practice-based research, consultant in healthcare projects and clinical pharmaceutical consulting. He has held positions such as Clinical Pharmacist, Clinical Specialist, Pharmacotherapeutic Specialist within teaching hospitals, as well as Manager of Government Affairs and Medical Affairs, Medical Science Liaison, and Senior Health Sciences Advisor in research-based pharmaceutical companies and was the Chief Operating Officer at Network Healthcare. Alan is a Certified Clinical Densitometrist (CCD), coauthored “The Osteoporosis Book, 4th Edition: Bone Health”, has numerous publications in scientific and health journals, newsletters, and is a founding co-editor of the Pharmacy Management in Canada textbook.

Alan has been an active member and past participant on various committees (with the College of Pharmacists of BC, BC Pharmacy Association, Canadian Pharmacists Association, Canadian Society of Hospital Pharmacists, GI Society, etc). He has interests in the areas of, rheumatology, osteoporosis, gastroenterology, diabetes, and cardiology. Alan enjoys being involved in projects that improve health knowledge translation, healthcare delivery, medical health education and health outcomes research. Alan’s training includes a Bachelor of Science in Pharmacy, a Hospital Pharmacy Residency at St. Paul’s Hospital, and Doctorate of Pharmacy degree at UBC. He is frequently invited to speak at regional, national and international conferences. He strives to develop solutions to close gaps in health care working together with a variety of people.

John Matheson was Director of Finance for the NHS in Scotland from 2008 until his retiral in 2016 with specific responsibility for health technology and innovation. Prior to that he was the Director of Finance at NHS Lothian. He studied at Heriot Watt and Edinburgh Universities.

John was a Council member of the Chartered Institute of Public Finance and Accountancy for 10 years and became President in 2015. Whilst President he focussed on raising the international profile of the Institute including presenting at a number of international conferences and he chairs a committee developing its global strategy.

Currently John chairs the Audit and Risk Committee and provides strategic advice to Transport Scotland. He is a member of the Doctors and Dentists Review Board. He also acts as a Consultant for Digital Health and Innovation Centre at University of Strathclyde. He was also a visiting Professor at Kwansei Gukain University in Osaka Japan.

He was awarded a CBE in 2015 for services to the NHS in Scotland.

Professor George Crooks is currently the Chief Executive of the Digital Health and Care Institute, Scotland’s national innovation centre for digital health and care. He leads an organisation that is tasked with delivering innovation in digital health and care that will help Scotland’s people to live longer, healthier lives, deliver sustainable health and care services for the future and create economic benefits for Scotland. DHI provides opportunities for Scotland’s public sector, academia and industry to co-design digital solutions to some of the country’s biggest health and care challenges working with patients, service users and their families.

He was previously the Medical Director for NHS 24, the Scottish Ambulance Service and Director of the Scottish Centre for Telehealth & Telecare. George was a General Medical Practitioner for 23 years in Aberdeen latterly combining that role as Director of Primary Care for Grampian. George is on the Board of the European Connected Health Alliance and is a past president of the European Health Telematics Association. He is a Board member of TEC Quality, a UK organisation leading the implementation of quality standards and practices across the assisted living sector in the UK. He was an assessor for the European Commission on programmes involving digital health and care provision and is a member of the WHO roster of experts for digital health. He has been an advisor to several European governments and global organisations including the World Bank on digital health and care. He has been appointed as a Bevan Commissioner for Wales and is an advisor to Innovate UK for its Industrial Grand Challenge programme for Health Ageing. He is also an adjunct Professor of Telehealth at the University of Southern Denmark.

He was awarded an OBE in the Queen’s New Year Honours List 2011 for services to healthcare.

From 2013 to 2017, John served in the BC Public Service as Deputy Minister of Technology, Innovation and Citizens’ Services. With 1,300 employees and an annual budget of more than $1 billion, the ministry delivered a broad spectrum of government services and economic development programs.

The ministry was responsible for the government’s cyber security strategy and operations, as well as the privacy and freedom of information files. John continues to have a strong interest in the development of privacy and security practice and policy.

Prior to joining the public service, John held a series of senior executive roles in public and private technology companies. Two of his President and CEO roles were with publicly traded companies regulated by both Canadian and United States securities regulators.

Beyond his public service and corporate work, John has long been active in the not-for-profit sector. He was on the Board of the Digital Identity & Authentication Council of Canada (DIACC) from 2013 to 2017 and as a senior board volunteer with a national health charity from 1994 to 2008.

Dr Fiona Duncan is a family physician at Chaldecott Medical Clinic in Vancouver, where she has practiced since 2002. Graduating with a BA and an MD from UBC, she moved east to Thunder Bay for residency in McMaster’s Rural Family Medicine Program, returning home to Vancouver in 2001.

In addition to her own private practice, Dr. Duncan is a Clinical Assistant Professor in the UBC Department of Family Practice and spent 10 years working with Vancouver Coastal Health on Vancouver’s Downtown Eastside, providing primary care, addictions and hepatitis C treatment. Since 2013, she has been involved in physician leadership and systems change, initially as a board member of the Vancouver Division of Family Practice, then as a member of the General Practice Services Committee, and currently as the Physician Lead for the Vancouver Division of Family Practice.

My name is Sarah Hamilton I am a mother of 3 teens, a wife of 20+ years, an enthusiastic athlete, and an advocate of using technology to achieve better health outcomes. I was employed many years as a sales professional in the high tech industry with a focus in healthcare.

My life was flipped upside down in 2017 when I was diagnosed with a cerebellopontine meningioma(brain tumor). Then an 11 hour craniotomy followed to remove the large tumor that was fully compressing my brain stem.

For about 10 years this tumor grew in my head but in the last 18 months before diagnosis I experienced a multitude of health related issues from the tumor. After surgery it left me with new deficits & challenges with my vision, hearing, balance, Cognitive abilities and a debilitating startle symptom. As a million dollar patient my recovery path now is giving back by blending my unique patient experience with my health technology background, tied in with my enjoyment of public speaking; to help improve health outcomes for all. I have an unique understanding of what it is like to navigate the health system which provides me with important insights on the needs, preferences and values that are important to users of the system. Through the sharing of my health care journey, my advisor role offers valuable insight on what healthcare does well and where we can make improvements. One of my key learns is that I need to advocate for myself in the healthcare system. I am Empowered to be the positive voice of the patient in partnering with healthcare initiatives.

Holly is a PhD level trained ethicist and research consultant. She serves as an ethicist on a US-based IRB and is an Adjunct Professor in the Faculty of Health Sciences at Simon Fraser University. She has worked as a consultant for Health Canada, the Public Health Agency of Canada, and the CIHR Ethics Office and her work has been published in a variety of journals including CMAJ, Trends in Neurosciences, and Cell Stem Cell. Her current Director role at the Provincial Health Services Authority (PHSA) of British Columbia reflects PHSA’s commitment to strengthening its research enterprise in support of its fundamental mandate to conduct world class research as an academic health science organization with an integrated mandate to deliver care, conduct research, and train tomorrow’s providers.

Joerg Schwarz is currently Senior Director for Healthcare Interoperability Solutions and Strategy at Infor with over 25 years of experience in the Healthcare Industry and in the interoperability space specifically. Prior to Infor, Joerg worked as a Director at GE Healthcare and Agfa Healthcare, designing and implementing solutions for medical image- and document- exchange and integrated care. He also worked at Boutique Healthcare firms such as NextGate (EMPI) and Audacious Inquiry (ADT Data Intermediary), and he built and directed a $500M Healthcare & Life Sciences Line of Business at the Fortune 500 company Sun Microsystems until it was acquired by Oracle.

Besides Healthcare IT, his passion is Business Intelligence and Data Analytics. Joerg teaches Business Analytics as a Distinguished Adjunct Professor at Golden Gate University’s Ageno School of Business in San Francisco for over 12 years. He holds a Master of Science degree in Information Systems from the University of San Francisco and a business administration and management degree from the Technical University of Cologne in Germany.

Tara McCarville is Principal Consultant at Brighton Group, a health industries solutions firm. As the former National Health Industries Leader for PwC Canada, Tara was accountable for leading a national practice focused on improving outcomes for government, hospital, healthtech/medtech, home/long term care, and private equity clients. In her role at Brighton, Tara is working with clients in both the public and private sector with crisis management, growth strategy & value creation, operational transformation, talent & leadership support.

Tara is on the Board of WELL Health (TSX: WELL), Starling Minds and is Chair of the Board at ALAViDA.

With a professional background in healthcare, management consulting and telecom, Tara has over 20 years of experience providing senior leadership in the private, public and not for profit sectors. She is an experienced, senior health executive who translates complex strategy to high performing operations, while developing talented and accomplished individuals and teams.

Tara holds a Master of Public Administration (MPA) from the University of Victoria, a Bachelor of Arts, Honours (BAH) from Queen’s University and an International Baccalaureate (IB) from the Lester B. Pearson United World College. She is a Certified Health Executive (CHE) and a Project Management Professional (PMP).

Pieter R. Cullis, Ph.D. FRSC, FNAI (USA), Scientific Director & CEO, NanoMedicines Innovation Network,  Canada’s National Centre of Excellence in nanomedicines; Professor, Department of Biochemistry and  Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the design and development of nanomedicines employing lipid nanoparticle  (LNP) technology for cancer therapies and gene therapies. This work has contributed to five drugs that have been approved by regulatory agencies in the U.S., Europe and Canada. Dr. Cullis has co-founded  ten biotechnology companies that now employ over 300 people, has published over 350 scientific articles and is an inventor on over 60 patents. He also co-founded the Centre for Drug Research and  Development, a Centre of Excellence for the Commercialization of Research (now AdMare) in 2004, the  Personalized Medicine Initiative (PMI) in 2012 and the NanoMedicines Innovation Network in 2019. Dr.  Cullis was elected a Fellow of the Royal Society of Canada in 2004 and was also awarded the Prix Galien,  Canada’s premier prize for achievements in pharmaceutical R&D, in 2011. Two recently approved drugs that are enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is BNT162b2, the COVID-19 vaccine developed by Pfizer/BioNTech that has now (December 2020) been approved in Canada, the USA, the UK and Europe. It is anticipated that more than 1.3B doses of BNT162b2 will be administered worldwide in 2021.

Paul Krzyzanowski, PhD, MBA, is the Medical Director, Precision Medicine for Janssen Canada. In this role, he leads the design & execution of Janssen’s precision medicine diagnostics strategy in Canada. His work involves bringing together diverse internal and external stakeholders with scientific, regulatory, and/or commercial perspectives to collaboratively tackle the challenges facing the adoption of precision medicine testing across the country.

Prior to joining Janssen, Dr. Krzyzanowski was the Director of the Translational Genomics Laboratory at the Ontario Institute for Cancer Research (OICR), the first laboratory in Canada to offer validated whole genome sequencing assays under CAP and IQMH accreditations. At OICR, he led his team to productionize and scale up many genomic assays to support oncology research including clinically reported whole genomes & transcriptomes. He was also an Adjunct Lecturer at the Department of Laboratory Medicine and Pathobiology, at the University of Toronto.

Dr. Krzyzanowski has co-authored over 26 peer-reviewed publications and book chapters and is also the co-inventor of several patents in the field of genomic technologies and bioinformatic gene signature development. He holds a MBA from the Rotman School of Management, University of Toronto, a PhD in Molecular Medicine from the University of Ottawa, a BSc(Honours) from the University of Toronto, and was a CIHR-funded Postdoctoral Fellow at OICR.

Dr. Pollard is a Senio​r Methodologist within the Department of Cancer Control Research at BC Cancer. She is a co-investigator on the Genome Canada funded, Canadian Network for Learning Healthcare Systems and Cost-Effective ‘Omics Innovation (CLEO), as well as the newly launched PRecision Oncology Evidence Development in Cancer Treatment (PREDiCT) Program. Dr. Pollard serves as a member of the Terry Fox Research Institute Marathon of Hope Cancer Centres Network (TFRI-MOHCCN) Health Technology Assessment Working Group, convener for the International Health Economics Association’s Economics of Genomics and Precision Medicine Special Interest Group, and faculty instructor in regulatory science with the University of British Columbia’s (UBC) Academy of Translational Medicine.

Dr. Pollard holds a Bachelor of Arts in Philosophy from UBC, a Master of Science in Health Research Methodology from McMaster University, and a PhD from UBC’s School of Population and Public Health. Her mixed-methods research program aims to generate evidence to support values-informed, timely, and appropriate integration of precision medicine across Canadian healthcare systems. Central to this work is the integration of patient, public, clinician, and decision maker perspectives into the evidence base upon which reimbursement and implementation decisions are made.

Bringing more than 35 years of experience in healthcare-related industries, Dianne currently serves as the Senior Vice President of the Government Division at Alberta Blue Cross. With a strong track record of establishing strategic and innovative partnerships, she is known for challenging the norm rather than moving with it, both at work and in her community. This coupled with her natural intuition and curiosity has led to groundbreaking initiatives in support of improved health and wellness outcomes for the communities she serves.

Dianne works closely with senior government officials—both provincial and across Canada—and a broad sector of the health industry including, pharmaceutical and medical, to foster effective working relationships. Focused on delivering quality results coupled with strong leadership, Dianne is highly engaged as both a director and board chair for various organizations and foundations. Dianne is currently actively serving as a board director for The Royal Alexandra Hospital Foundation, the Women and Children’s Health Research Institute and Edmonton Health Cities.

Dianne strives to make a positive difference in peoples’ lives. With her certification as an Executive Coach through Royal Roads University, she works to inspire and empower individuals to tackle challenges with gusto and to never accept anything less than incredible as an outcome. She looks forward to an engaging dialogue with you.

Joby McKenzie is the Managing Director of Teladoc Health in Canada responsible for all strategy and operations, growing whole person virtual care to empower Canadians to live healthier lives. Dr. McKenzie also volunteers as a Board Director at Mackenzie Health overseeing their strategic, quality and financial plans and decisions.

Previously, Dr. McKenzie served as the Managing Director at Babylon Health in Canada, where she led the exponential adoption of virtual primary care across Canada. Prior to that, she held executive roles at LifeLabs (medical diagnostic services) in business development, post-merger integration, government relations and strategy and was a consultant at the Boston Consulting Group (BCG) where she worked with clients in healthcare and financial services and helped them to increase shareholder value. Dr. McKenzie was also an international professional basketball player and Canadian national athlete including qualifying for the 2000 Olympics and receiving a silver medal at the 1999 PanAm Games.

Dr. McKenzie has an MBA from the Ivey School of Business, a Doctor of Philosophy in Molecular and Medical Genetics from the University of Toronto and a Bachelor of Science in Molecular Biology and Biochemistry from Simon Fraser University.

Jeremy Mickolwin is WELL Health’s VP of Clinic Operations. He oversees the company’s primary care, speciality care and allied care network of clinics across Canada. Jeremy has a passion for technological, innovation and agile, future focused solutions within the healthcare industry. He is responsible for the digitization of patient experiences across WELL’s outpatient medical clinic network which is the largest in Canada. Jeremy has a Master of Health Administration from UBC and has worked in healthcare for 20+ years.

Thomas is a seasoned executive with over twenty years of strategy and operations experience with a core focus in health care. His areas of expertise include strategic planning, system design, service delivery modernization, and senior level stakeholder management within the context of whole health system transformation.

Thomas has partnered with stakeholders to advise on health system integration initiatives and to implement new organizational strategies and has experience working with groups on large change transformations. He is a Partner in Deloitte’s health care consulting practice based in Vancouver and the firm’s National Clients and Growth Leader for health care, where he works with providers, payers, and private companies across the country on some of their most significant business initiatives.

Thomas has established deep relationships with senior administrative and clinical leaders across the British Columbia health sector through his many strategic engagements with the Ministry of Health, Health Authorities, unions, research institutions as well as the rich life sciences ecosystem.

Prior to his Deloitte appointment, Thomas served as leader of health care advisory services at KPMG in British Columbia. In addition to his work in Western Canada, Thomas served as a member of the Senior Executive Team at one of Ontario’s Local Health Integration Networks, where he led health system planning and strategic engagement portfolios. Thomas has also served in various senior management roles at the Ontario Ministry of Health and Long‑Term Care, where he developed and implemented large scale transformation initiatives, particularly in the area of primary care reform and access to care.

Beginning in the early 2000s as a member of the Ontario Health Results Team that implemented Family Health Teams and Nurse Practitioner Led Clinics, as well as introduced new primary care payment models in the Ontario, Thomas has continued to work with and advise clients on primary care initiatives and is the author (with Dr. Monica Aggarwal) of Primary Care Innovations across Canada.

Wes Sylvester is the worldwide Vice President for Cisco Systems’ Industry Solutions Group. In this role, he is responsible for industry direction, vision, messaging, and growth. Wes’ team works with Cisco’s manufacturing, retail, utility, healthcare, education, financial services, transportation, government, oil & gas, and mining customers across the world to establish business case, architecture, and integrated communications network strategies for a variety of operational investments.

Wes has over 15 years of focused experience leading and building global marketing and sales teams at the director and VP level for major industry players including Cooper/Eaton, Siemens, and Philips/Signify prior to Cisco. Wes holds a BS in Mechanical Engineering from MSOE in Milwaukee, and an MBA from the University of North Carolina Kenan-Flagler Business School, with a concentration in Strategy and Leadership.

Wes and his family love living in Seattle, where you’re likely to find him on a hiking trail in his free time.

Dr. Salama has over 25 years drug discovery experience across several disciplines including the discovery and development of new antibacterial and antifungal agents. In addition to being the Chief Scientific Officer (CSO) of Fedora Pharmaceuticals Inc. (fedorapharma.com), he is also the CSO of Brass Dome Ventures Ltd. (brassdomeventures.com); Executive Board member of the Canadian Pandemic Preparedness Hub (CP2H), Advisor to the AMR Steering Committee, Public Health Agency of Canada (PHAC), Member of the Oversight Committee, Li Ka Shin Alberta Virology Institute (LKSAVI), an active member of the Multi-sectoral Federal, Provincial and Territorial Task Group on Antimicrobial Resistance for the Government of Canada; Chairman of the Canadian Antimicrobial (AMR) Resistance Innovation Coalition (CAIC); Director on the Board of Directors of BioAlberta (bioalberta.com), a biotechnology advocacy group representing the biotechnology sector of the Province of Alberta, Canada; Chairman of the Board of Al Rashid Education Foundation (alrashideducation.com), a not-for-profit organization promoting post-secondary education of marginalized communities; and involved in a number of not-for-profit organizations. He also held several senior positions in both the drug discovery and contract research sectors, including several vice-president roles.

In his scientific capacity, Dr. Salama played a senior role in the discovery and development of several antibiotics including beta-lactmas, beta-lactamase inhibitors, fluoroquinolones, azoles, polyenes, as well as several natural products.

Additionally, Dr. Salama is business development professional with nearly 20-year experience in strategic planning, evaluation of new business and scientific opportunities, partnership establishment and management, contract negotiations, as well as in-licensing and out-licensing of assets. He was actively involved in dozens of licensing and partnership agreements, including the licensing of Fedora’s Beta-lactamase inhibitors to F. Hoffman La Roche in a US$750 million license deal.

Dr. Salama received his Ph.D. in Microbiology from the University of Salford, UK, and published over 50 original research articles and presentations at international congresses. He is also an inventor on several original patents in the anti-infective and anti-inflammatory disease areas.

Emily Beduz is the Manager of Federal Affairs and Public Policy at GSK. Prior to this role, she served in the office of former Ontario Health Minister Christine Elliott in various policy roles until the onslaught of the pandemic, after which she took on the role of Director of Pandemic Response. Prior to the Minister’s election, Emily served in the Office of the Leader of the Official Opposition, working closely with the Ontario Health Critic.

John Conly is a Professor and former Head of the Department of Medicine at the University of Calgary and Alberta Health Services – Calgary and Area, Canada. He is medically trained as a specialist in infectious diseases, and was a past President of the Canadian Infectious Disease Society, past Chairman of the Board for the Canadian Committee on Antibiotic Resistance, a previous Vice Chair for the Canadian Expert Drug Advisory Committee, a previous Advisory Board member of the CIHR Institute of Infection and Immunity and an immediate past member of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He is currently the Chair of the WHO Infection Prevention and Control Research and Development Expert Group for COVID-19, a member of the WHO AMR Expert Group, a member of the Canadian AMR Task Force and a member of the AMR One Health Consortium at the University of Calgary. He has published over 500 manuscripts, book chapters, technical reports and guidelines and has received multiple career honours in teaching, research, mentorship, innovation and service, including the Ronald Christie Award for outstanding contributions to academic medicine in Canada, the Medal for Distinguished Service from the Alberta Medical Association for outstanding personal contributions to the medical profession, the Order of Canada and the FNG Starr Award from the Canadian Medical Association, considered the “Victoria Cross” of Canadian medicine. He continues as an active consultant in clinical infectious diseases with current interests which focus on antimicrobial resistance and stewardship, prevention of hospital-acquired infections and novel innovations in healthcare.

Dani Peters is President of Magnet Strategy Group, a consulting firm that manages public affairs strategies in Canada and the United States. She also serves as Senior Advisor to the Canadian Antimicrobial Innovation Coalition, a non-profit organization committed to preventing the rise in antimicrobial resistance (AMR), by positioning Canada to be a leader in AMR research and product development, economic growth, and investment.

Over the course of her career, Dani has supported the private sector in a variety of initiatives related to antimicrobial resistance and innovation in both the U.S. and Canada.

Dani is also co-founder of the Cross-Border Health Foundation, an organization that fosters dialogue between Canada and the United States around common health priorities. In addition to operating Magnet Strategy Group, Dani serves on the Industry Advisory Board for Bloom Burton & Co., a healthcare investment advisory firm in Toronto. She is also a Health Leader-in-Residence for the World Health Innovation Network (WIN), within the University of Windsor’s Odette School of Business.

Joan is the vice president of group benefits for CLHIA (Canadian Life and Health Insurance Association), a voluntary trade association with member companies that account for 99 percent of Canada’s life and health insurance business. In her role, Joan is responsible for analysis on industry issues, policy strategy development and to build consensus on concerns important to member companies. An important part of the health portfolio is working within industry, including with national healthcare associations as well as with provincial/federal payers on benefit programs, specifically on best practices, strategy, advocacy and sustainability. Joan has been with the CLHIA for more than 7 years, starting as Director of Health and Disability Policy.

Joan brings 20+ years of benefits management expertise to her position at CLHIA, having worked for insurers and administrators on both private and public sector programs, notably with First Canadian Health and Health Canada on the NIHB program and most recently with Medavie Blue Cross.

Since joining Victoria Hospice as CEO in 2018, Kevin has overseen the growth of programs and services, including a joint expansion with Island Health to nearly double the number of acute palliative and community hospice beds in the region; the opening of a new Community Support Centre, offering grief support and public and professional education workshops; and a thorough organizational review process with Accreditation Canada, resulting in the designation of Accreditation with Commendation. Kevin has deep expertise in leading organizations and spearheading national research aimed at driving innovation, improving quality of care, and creating services to improve the quality of life of Canadians and their caregivers. Kevin sits on several boards and was recently elected to be Chair of the board for the BC Hospice Palliate Care Association.

Dr. Eman Hassan is the executive director of the BC Centre for Palliative Care and the lead for the Centre’s public health portfolio. She has more than 20 years of experience leading population and community health initiatives in BC and abroad. Under Eman’s leadership, the Centre’s community-empowering interventions, including the Compassionate Communities initiative and advance care planning program, received national recognition either as an innovation or a best practice in community-based palliative care. In addition to her leadership of the BCCPC, Eman is an adjunct professor at the UBC Palliative Medicine Division. Throughout her career, Eman received notable awards from academic and research institutions. The latest award she received is the 2021 Convening and Collaborating Award from the Michael Smith Foundation for Health Research.

After earning his M.B.A. from Queen’s University, Stephen worked at Procter & Gamble and then at internet consulting firm, Cyberplex, where he worked with clients such as Sony, Chrysler, and Sprint to develop their internet strategies. He then founded and ran AllStarLineup for 12 years working with athletes and entertainers such as Magic Johnson, Pedro Martinez and Pamela Anderson, managing their promotional and business opportunities.

Stephen began work in the healthcare industry as Managing Director of the Mount Sinai Fertility Clinic in 2011, and in 2014 became the Director of Business Development at Mount Sinai Hospital. In 2016 he was named VP of Business Innovation & Development for the Sinai Health System, where he led all profit-generating businesses until 2021.

Stephen returned to the private sector in 2021 targeting two significant areas of interest and growth in global healthcare – he founded Paxana Med, a company focused on the use of psychedelics to treat Traumatic Brain Injuries, and joined Petal Health as VP, Business Development where he is responsible for the company’s growth in Canada and the US.

Dr. Pieter R. Cullis, PhD is a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, co-founder and co-chair of the Personalized Medicine Initiative, and director of the NanoMedicines Research Group at UBC. He has co-founded numerous companies and organisations, including Lipex Biomembranes Inc., Arbutus Biopharma, Northern Lipids Inc. (now Evonik), Acuitas Therapeutics and Precision NanoSystems, and the Centre for Drug Research and Development, where he was Founding Scientific Director from 2004 – 2010.

Cullis has contributed to fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule and macromolecular drugs. This work has contributed to three approved LNP products for the treatment of cancer and its complications and a fourth gene therapy drug to treat an hereditary condition that recently completed a most successful Phase 3 trial. He also works to influence the health care system to introduce personalized medicine based on molecular makeup of the individual and their disease.

Cullis has received numerous awards. He was elected as a Fellow of the Royal Society of Canada in 2004 and received the Journal of Drug Targeting’s Lifetime Achievement Award in 2016.

As President and Chief Executive Officer, Suzanne Gill leads Genome BC in applying the power of genomics in ways that better the lives of all British Columbians. Suzanne has been at the forefront of catalyzing sustainable, public-private partnerships across the life sciences ecosystem for more than 20 years. She provides a wealth of experience in the Canadian innovation environment, including economic development and stakeholder relations, and in helping to shape and implement strategy for organizations at the nexus of research, innovation and commercialization.

Suzanne is passionate about the important work of integrating genomics into society by supporting responsible research and innovation and fostering an understanding and appreciation of the life sciences, helping BC rise to the challenges of the 21st century.

Working with our partners, Suzanne’s focus is on building upon Genome BC’s successes in precision health, natural resources and education while growing BC’s thriving life sciences research and innovation ecosystem. Genomics has proven to be an important tool in the diagnosis and treatment of cancer, rare diseases and the prevention of adverse drug reactions. Genomics is also providing new and transformative ways to address BC’s environmental challenges, such as determining which plants and trees will be better able to adapt to new environmental conditions as well as identifying and managing invasive pests and disease-causing pathogens that pose threats not only to forests but also many fruit crops.

Previously, Suzanne was a founding executive as the Vice President, Government Relations and Public Affairs with the Digital Supercluster (2018-2022), an industry-led organization that aims to accelerate economic growth and position Canada for global leadership in transformative digital technologies. In addition to fostering an essential relationship between industry, academia and government, she also led the development and launch of Digital Supercluster’s inaugural Capacity Building Pilot Program aimed at connecting employers to job ready digital talent.

Prior to joining the Digital Supercluster, Suzanne was at Genome BC for over a decade and last held the role of Vice President, Corporate Development, responsible for corporate strategy, corporate performance management and government relations. She moved to BC following her work at the Ontario Genomics Institute as part of the start up team and was responsible for oversight of a $300 million research portfolio at the time when Canada was making its first large scale investments in research in the sector.

Suzanne holds an MSc degree from the University of British Columbia and an MBA from the Schulich School of Business at York University in Toronto. She has been on the Board of Directors of Innovate BC since 2018.

Sarah Dewell PhD MSc RN is an Assistant Professor in the School of Nursing at the University of Northern British Columbia. Her research explores the development of precision health through scholarship focused on nursing education, research, and practice with an emphasis on foundational genomic knowledge for all nurses. Sarah completed a BSc in Cell Biology and Genetics and a Masters in Medical Genetics at the University of British Columbia. She completed a BN and a PhD at the University of Calgary. Sarah is a member of the steering committees for the Global Genomics Nursing Alliance (G2NA) and the Canadian Nursing & Genomics initiative. She is also a member of the International Society of Nurses in Genetics (ISONG).

Dr. Anna Lehman is Medical Director of the Adult Metabolic Diseases Clinic at Vancouver General Hospital and Associate Professor of Medical Genetics at the University of British Columbia. Her research program has focused on identifying genetic causes for rare diseases and on improving the diagnostic process for people with genetic disorders.​

Presently, Dr. Lopez-Correa is the Chief Scientific Officer (CSO) at Genome Canada. As CSO, she is taking genomics to the next level in Canada, by advancing mission driven initiatives using genomics to solve the most pressing global challenges. Previously, she was Executive Director of the Canadian COVID19 Genomics Network (CanCOGeN), a $40M initiative to advance the use of genomics to help us understand and control the COVID19 pandemic. She also held the position of COO at Ruta N Medellin, driving innovation ecosystems to advance social and economic development in Colombia and Latin America. Prior to that, Dr. Lopez-Correa was the CSO at Genome BC (2016-2019) and at Genome Quebec (2008-2015) where she was instrumental in developing competitive teams for national and provincial research and innovation initiatives raising the profile of Canadian genomics on the global stage. Dr. Lopez-Correa has also held leadership positions at deCODE Genetics, and Eli Lilly and has played advisory roles at the European Commission, Innovative Medicine Initiatives and other private and public sector entities working in the application and implementation of genomics technologies. As part of her commitment to international development, Dr. Lopez-Correa has led several initiatives aimed at demonstrating the impact of genomics and innovation in developing countries. She is also fully committed to advance equity, diversity and inclusion, with a particular interest in gender equity in science. Dr. Lopez-Correa has been recognized with several awards: in 2017 she received the Canadian Senate 150th Anniversary Medal, in 2013 she was recognized by National Order of Merit Award in the Rank of Officer from the Republic of Colombia.

Dr. Lopez-Correa holds an MD from the Universidad Pontificia Bolivariana in Colombia, an MSc in Human Genetics from Paris V University in France, a PhD in Medical Sciences from the KULeuven in Belgium, and a mini-MBA from McGill University in Canada.

Glynda Rees RN MSN ACHIP FAMIA teaches in the BSN program at the British Columbia Institute of Technology (BCIT) in Vancouver, British Columbia, and is Program Lead for the development of an Advanced Certificate in Digital Health at BCIT. She completed an MSN at the University of British Columbia with a focus on education and health informatics, and a BSN at the University of Cape Town in South Africa.

Glynda’s interests include digital health education, the impact of health information technologies on clinical judgment and decision making at the point of care, and the potential for health information technologies to improve health outcomes across communities.

Glynda co-authored the Open Educational Resources Clinical Procedures for Safer Patient Care and Health Case Studies, and the Digital Health Nursing Informatics E-Resource with the Canadian Association of Schools of Nursing. Glynda is currently co-leading a provincial initiative to develop an Interprofessional Educational Electronic Health Record for teaching and learning in healthcare.

Chris Eagle trained as a cardiac anesthesiologist and had a successful academic career culminating as Professor Emeritus at the University of Calgary. He has held a number of leadership positions including President and COO of the Calgary Health Region, President and CEO of Alberta Health Services, President and CEO of the Calgary Health Trust. He has served as a Board member on a number of health organizations including the Health Quality Council of Alberta and the Canadian Institute for Health Information. Currently, he is chair of the board of trustees of the Alberta Cancer Foundation, and is an advisor on healthcare matters to the Enoch Cree Nation.

Allie DeLonay is a Data Scientist on the Data Ethics Practice team at SAS. Allie earned her bachelor’s degree in Sociology with a concentration in analysis and research and earned a global health certificate at the University of Wisconsin – Madison. In 2019, she earned her master’s degree in Data Science, also from the University of Wisconsin, which was when she was formally introduced to the area of data ethics.

Prior to working at SAS, she spent 9 years working as a Data Scientist for the Health Innovation Program, a health services research organization at the University of Wisconsin – Madison. Her passion in data ethics led her to not only develop AI systems, but also to evaluate whether the AI systems she helped to develop and deploy in the healthcare system could negatively harm vulnerable populations. It was this passion for data ethics that brought her to SAS.

In her current role within the Data Ethics Practice at SAS, Allie works with research & development teams to brainstorm and implement the responsible and ethical AI features required for SAS to substantiate their claim as a leader in responsible innovation.

Alina is the Co-Founder/Co-President of HelpSeeker Technologies – a social technology and innovation Alberta-based B-Corp, founded in 2018. Her background is as a social scientist with a specialization in systems planning and integration, and as a funder and social policy expert. She’s had the opportunity to work in systems change efforts on homelessness and affordable housing, domestic violence, poverty, mental health, and addictions throughout her career. Alina’s drive and passion for her work are grounded in her lived experience of the social issues she continues to challenge in her professional work. Her most recent interest is in putting new technologies to use in reforming the design and delivery of social safety nets.

Jimmy serves as a program executive on a number of key health accounts spanning government, provider, and with leading health technology and pharmacy providers. Jimmy has worked extensively in the health care and life sciences sectors, spanning hospitals, government, agencies, primary/seniors/rural care, clinical research organizations, and pharmaceutical companies. He specializes in corporate strategy, clinical and health system planning, and growth model business planning. He works with leaders who are focused on improvement and transformation, through business and clinical process innovation, and enabled and powered by analytics, AI, and technology.

He has previously held roles at Schering Plough, GlaxoSmithKline, Deloitte Consulting, and Garrison Health. Additionally, he co-founded and serves on the board of Red Maple Trials Inc., a clinical research organization (CRO) that works with biotechnology and pharmaceutical companies, supporting phases I through IV research programs in specific therapeutic areas. Jimmy is a faculty member in the Health Industry Management Program at the Schulich School of Business, York University, where he teaches graduate students in the areas of new business models and convergence approaches in health care and life sciences. He also serve as a Volunteer Advisor in the MaRS Health Venture Services program.

Dr. Robert Fraser is the President and CEO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.

As Vice-President, Value Access & New Product Planning at Novartis Pharmaceuticals Canada Inc., Thea Discepola manages a team at head office and across Canada that is responsible for ensuring that Novartis and its innovative medicines are known and understood by key stakeholders and that the medicines are readily available to Canadian patients through private and public drug plans. The team is responsible for health economics studies and outcomes research, provincial policy matters, pricing, reimbursement strategies, as well as new product planning.

Thea has been with Novartis for 20 years where she began her career as Legal Counsel in 2002. Over that period, she took on positions of increasing responsibilities within her field, managing a team accountable for legal, compliance and corporate matters for the Novartis Canada entity. She was eventually promoted to Vice-President of Legal, Compliance & Country General Counsel in 2013. Over and above her Legal duties, she took on the responsibilities of Ad Interim President at Novartis Pharma Canada in March 2019 for 4 months. Thea joined the Market Access team as Vice-President in March of 2020 just as the COVID-19 pandemic hit and has managed to successfully lead a team of almost 40 people virtually.

Thea brings to the team a high level of adaptability, curiosity, knowledge, drive and empathy along with an overall understating of the Canadian pharma organization which are key assets when facing the challenges in health policy and patient access in Canada.

Thea has a Law degree from the University of Montreal. She is trilingual and has a passion for travelling, music and spending time in nature.

Craig Ivany is a health services executive and laboratory services strategist with over 35 years of experience influencing healthcare. His depth of practice includes a legacy of leadership across Canada, including Hospital Executive Director in rural Newfoundland, Executive Director of Canadian Blood Services’ operations portfolio, VP role with DynaLIFE in Alberta, VP role with Dynacare Laboratories in Ontario, CEO of the Eastern Ontario Regional Laboratory Association, President and CEO of Alberta Public Labs, and is a current and past board member of several not-for-profit organizations in Canadian healthcare. In his current role, as the Chief Provincial Diagnostics Officer with Provincial Health Services Authority (PHSA), Craig is leading the implementation of a new province-wide laboratory medicine service delivery model in collaboration with stakeholders across British Columbia. Craig is a certified health executive, a long-time member of the Canadian College of Health Leaders, holds an ICD.D with the Institute of Corporate Directors and is an Adjunct Professor, Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia.

Dr. Evgueni Loukipoudis is the Chief Technology Officer of Circle Innovation. Prior to this role, Dr. Loukipoudis was the CTO of the Digital Technology Supercluster where he inspired and supported innovative and collaborative projects to deliver over 150 novel products and services. He was also the CTO of McKesson Medical Imaging and Change Healthcare between 2015 and 2018. Prior to moving to Canada, he worked for Agfa Healthcare where he co-led the digital transformation team. Evgueni has has extensive international experience having worked in Belgium, Germany, Brazil and North America. He holds an MSc in Mathematics and a PhD in Computer Science from the University of Sofia, Bulgaria. His interests include digital health, digital twins, distributed ledger technology, data commons, web3 data economy, linked open data, and machine learning.

Tim Murphy has more than 30 years of senior executive experience in the health care sector. Currently, he is the Vice President, Health at Alberta Innovates and prior to this role, he was the Vice President, Provincial Platforms and SPOR.

Before joining Alberta Innovates, Tim established an independent consulting practice and worked with clients such as the Institute for Health System Transformation and Sustainability, and the Movember Foundation.  His other roles have included being the inaugural Senior Vice President at the Michael Smith Foundation for Health Research (MSFHR), and 10 years in senior management positions with two comprehensive Academic Oncology Centres: Princess Margaret Hospital (1992‐1997) and the British Columbia Cancer Agency (1997‐2002).

Tim holds a Master of Health Administration from the University of Toronto (1992), a Master of Business Administration from Queen’s University (2006), and a Certified Professional Accountant (CPA) designation.

DURHANE WONG-RIEGER, PHD is President & CEO of the Canadian Organization for Rare Disorders, Chair of the Consumer Advocare Network, President & CEO of the Institute for Optimizing Health Outcomes and Chair of Canadian Heart Patient Alliance.

Internationally, she is Chair of Rare Disease International, Chair of Asia Pacific Rare Disease International, Treasurer of United Nations Nongovernmental Organization for Rare Diseases. Chair of Patient Advocates Constituency Committee of the International Rare Disease Research Consortium, Patient Advisor to the APEC Rare Disease Network, member of the Editorial Board of The Patient- Patient Centred Outcomes Research, member of the Global Commission to End the Diagnostic Odyssey for Rare Diseases and member of Health Technology Assessment International Patient /Citizen Involvement Interest Group.

Dr. Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of Ontario’s Rare Disease Implementation Working Group and member of Genome Canada Steering Committee for the Rare Disease Precision Health Initiative. She is a certified Health Coach.

Durhane has a PhD in psychology from McGill University and was professor at the University of Windsor, Canada. She is a trainer and frequent lecturer and author of three books and many articles.

Dr. Alan Low is the Executive Director of Medicines Access Coalition – BC, Primary Care Pharmacist and Pharmacy Lead at BioPro Biologics Pharmacy, a collaborative practice approach, focusing on patient centred care. He is also a Clinical Associate Professor in the Faculty of Pharmaceutical Sciences at UBC and an Instructor and Course Developer with the School of Health Sciences at the Justice Institute of BC (JIBC).

Convinced that pharmacists have much more to offer to the public and the healthcare system, Alan has led the development and implementation of provincial medication management projects in BC and Alberta as well as creating a novel model of community pharmacy practice where interprofessional collaboration is leveraged to improve patient health outcomes.

Within the Faculty of Pharmaceutical Sciences at UBC, Dr. Low is one of the founders of the Faculty based Pharmacists Clinic and helped develop and lead the business case for the Pharmacists Clinic. He is the Course Coordinator for the Pharmacy Practice Management and Leadership Course and Lecturer. In addition, he is also a Board Advisor with the GI Society and sits on the Medical Board of HealthChoicesFirst.com, a patient video education resource. Dr. Low has experience in a wide variety of health and administrative settings including direct patient care in the hospital and clinics, clinical and practice-based research, consultant in healthcare projects and clinical pharmaceutical consulting. He has held positions such as Clinical Pharmacist, Clinical Specialist, Pharmacotherapeutic Specialist within teaching hospitals, as well as Manager of Government Affairs and Medical Affairs, Medical Science Liaison, and Senior Health Sciences Advisor in research-based pharmaceutical companies and was the Chief Operating Officer at Network Healthcare. Alan is a Certified Clinical Densitometrist (CCD), coauthored “The Osteoporosis Book, 4th Edition: Bone Health”, has numerous publications in scientific and health journals, newsletters, and is a founding co-editor of the Pharmacy Management in Canada textbook.

Alan has been an active member and past participant on various committees (with the College of Pharmacists of BC, BC Pharmacy Association, Canadian Pharmacists Association, Canadian Society of Hospital Pharmacists, GI Society, etc). He has interests in the areas of, rheumatology, osteoporosis, gastroenterology, diabetes, and cardiology. Alan enjoys being involved in projects that improve health knowledge translation, healthcare delivery, medical health education and health outcomes research. Alan’s training includes a Bachelor of Science in Pharmacy, a Hospital Pharmacy Residency at St. Paul’s Hospital, and Doctorate of Pharmacy degree at UBC. He is frequently invited to speak at regional, national and international conferences. He strives to develop solutions to close gaps in health care working together with a variety of people.